Skip to content

Clinical trial for Comparative Study on the effect of oral intake of LB-P9 on maintaining hair health(Random Allocation, Double Blindness, Control Comparison)

Clinical trial for Comparative Study on the effect of oral intake of LB-P9 on maintaining hair health(Random Allocation, Double Blindness, Control Comparison)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0009499
Enrollment
80
Registered
2024-06-03
Start date
2022-11-21
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Once a day, one capsule is taken after dinner with water for 24 weeks of test or control food. The test food is a capsule formulation combined with LB-P9, and the control product

Sponsors

LISCure Biosciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Men and women aged 18 to 60 with mild or more damaged hair without healthy hair loss disease - Adult men and women with a gloss score of 1 to 3 according to the visual evaluation classification method, and a total score of hair damage assessed according to exposure to risk factors, less than 18. 2) Subjects who will not engage in any special hair products or hair care and manipulation during the study period 3) Those who have agreed to maintain the same hair shape, color and length during the study period - Those whose hair length is 8cm or more when measured from the top of the head 4) A person who voluntarily agrees to participate and signs a written consent form before the start of this human body application test

Exclusion criteria

Exclusion criteria: 1) Severe acute kidney or heart disease that could affect the results of the trial in the last six months 2) Patients with hypertension who are not controlled during screening (blood pressure 180/110mmHg or higher; however, those who are stably controlling blood pressure with drug treatment can participate) 3) Diabetes patients who are not controlled during screening (HbA1c 9% or more) 4) Patients with uncontrolled hyperthyroidism or hypothyroidism at screening time 5) In clinical laboratory examination results during screening, creatinine concentration is more than twice the upper limit of the research institute, or patients with chronic renal failure or kidney disease requiring dialysis 6) At screening, clinical laboratory examination results show that AST or ALT concentrations are more than twice the normal upper limit of the research institute, or drug/alcoholic hepatitis, cirrhosis, fatty liver patients requiring treatment 7) a person who complains of severe gastrointestinal symptoms 8) A person with a history of malignant tumors within the past 5 years 9) a person with a psychiatric condition 10) A person with an infectious skin disease 11) Patients with other hair loss diseases such as androgenic alopecia, atypical alopecia, resting alopecia, and scarring alopecia 12) A person who is pregnant, lactating, or planning to become pregnant 13) Those who have taken oral Dutasteride or Finasteride in the last 6 months 14) Those who have been applying local hair growth agents, wool, and hair growth agents for the past month 15) Those who have taken the following drugs in the last 1 month: Steroids, apoptosis, vasodilators, antihypertension, anti-interstitial drugs, beta receptor blockers, bronchodilators, diuretics, Cimetidine, Diazoxide, Cyclosporine, Ketoconazole 16) Those who have been applying topical steroids to their scalp for the past month 17) Those who have been taking lactobacilli preparations within the last month 18) A person who has taken drugs that may affect hair growth within three months or is currently taking them 19) A person who has consumed functional health food recognized by the Ministry of Food and Drug Safety within three months prior to the start of the test 20) A person who participated in other human application tests and clinical trials within three months prior to the start of this human application test 21) A person whose alcohol intake falls under the following (men's 40g/day or more, women's 20g/day or more, alcohol 40g=17 degree soju 0.8 bottles or 1L of beer) 22) Those who are allergic or have side effects to test foods 23) A person who is deemed unsuitable for the examination by the examiner for other reasons

Design outcomes

Primary

MeasureTime frame
Hair gloss

Secondary

MeasureTime frame
visual evaluation of hair gloss by three independent experts;satisfaction evaluation of study subjects through questionnaire;hair elasticity;evaluation by researcher's questionnaire(subjective stimulation);evaluation by researcher's visual observation(objective stimulation);abnormal changes in hematological/blood chemical test values;whole-body evaluation by biological signs and questionnaire and abnormal findings

Countries

Korea, Republic of

Contacts

Public ContactEUN JI LIM

P&K Skin Research Center

ej.lim2@pnkskin.com+82-2-6925-1501

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026